The Rx Recap: April 6-12

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

FDA Grants Full Approval to Vitrakvi For NTRK-Positive Solid Tumors

Research reported by CURE highlights that the FDA has granted full approval to larotrectinib (Vitrakvi) for adult and pediatric patients with NTRK gene fusion-positive solid tumors that are metastatic or surgically unresectable with no satisfactory treatment alternatives. This marks the first full approval of an NTRK inhibitor, following its accelerated approval in 2018. Backed by results from three clinical trials, larotrectinib demonstrated a 60% objective response rate and a median response duration of over 43 months, offering a durable and targeted option for patients with these rare cancers.

Study Suggests AI Software May Offer Standalone Value for X-Ray Detection of Pediatric Fractures

Research reported by Diagnostic Imaging highlights promising findings for RBFracture, an AI software developed by Radiobotics, in detecting pediatric fractures on X-rays. In a retrospective study of 1,672 pediatric patients, the AI demonstrated strong standalone performance with 92% sensitivity, 83% specificity, and 87% accuracy. It was especially accurate in identifying proximal tibia (100%) and medial malleolus (96%) fractures, though its performance was lower (68% sensitivity) for radial condyle fractures, suggesting room for improvement in detecting subtle elbow injuries. When used alongside resident physicians, the software modestly boosted diagnostic performance, indicating its potential as a valuable tool in pediatric emergency settings.

Thermocool Smarttouch SF Catheter Demonstrates High Efficacy in Patients with Atrial Fibrillation

According to Applied Clinical Trials, 1-year results from the SmartfIRE trial demonstrate that Johnson & Johnson’s dual energy ThermocoolSmarttouch SF catheter—which integrates pulsed field (PF) and radiofrequency (RF) ablation—achieved 86.9% efficacy in treating drug-refractory paroxysmal atrial fibrillation (AFib). The study involved 149 European patients and also showed a 40.8% reduction in cardiovascular-related hospitalizations and 60.4% decrease in class I/III antiarrhythmic drug use, with minimal adverse events. These findings underscore the catheter’s effectiveness and safety, while ongoing research, including the GPfIRE and REAL AF Registry studies, aims to further explore its role in optimizing AFib care amid a growing global burden.

Study Explores Natural Product Use Among Veterans, Including Cannabis for Pain

According to Cannabis Science and Technology, a recent survey conducted as part of the ongoing wHOPE study explored natural product (NP) use—including cannabis—among US veterans managing chronic pain. Published in Global Advances in Integrative Medicine and Health (Feb. 2025), the survey involved 52 veterans, most of whom reported daily chronic pain. Findings showed that 40% used cannabis products, primarily blends of CBD and THC, with common reasons including pain or mobility (81%), sleep (62%), and PTSD or anxiety (43%). Vitamin D, multivitamins, and cannabis were among the most frequently used NPs. The study also highlighted a trend of NPs replacing traditional medications, raising potential safety concerns. Researchers emphasized the need for better provider-patient communication about NP use and noted the survey’s promise as a tool for future, broader studies.

FDA Clears Dexcom G7 15 Day, Marking the Longest-Lasting CGM System

According to Pharmacy Times, Dexcom has launched its G7 15 day continuous glucose monitoring (CGM) system, now recognized as the most accurate CGM for adults, with a mean absolute relative difference of 8%, as presented at the 2025 ATTD conference in Amsterdam. This next-gen device extends wear time to 15.5 days, reducing waste and the number of required sensors while improving glucose tracking precision. The system maintains all the advanced features of its predecessor, including real-time sharing, waterproof design, and direct Apple Watch connectivity.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.